Electroencephalographic features of convulsive epilepsy in Africa: A multicentre study of prevalence, pattern and associated factors

Symon M. Kariuki a,b,* , Steven White c, Eddie Cheng o,d , Ryan G. Wagner e,f , Kenneth A. Ae-Ngise g, Angelina Kakooza-Mwesige h,i, Honorati Masanja l , Anthony K. Ngugi k, Josemir W. Sander j,m, Brian G. Neville n, Charles R. Newton a,o, on behalf of SEEDS investigators, l

a KEMRI-Wellcome Trust Research Programme, P.O. Box 230, Kilifi, Kenya
b Nuffield Department of Medicine, University of Oxford, OX3 7BN Oxford, UK
c Department of Clinical Neurophysiology, Great Ormond Street Hospital for Children, WC1N 3JH London, UK
d Foundation for People with Epilepsy, 80200 Malindi, Kenya
e MRC/Wits Rural Public Health and Health Transitions Research Unit (Agincourt), School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, P.O. Box 2 Corintheek 1380, Johannesburg, South Africa
f Epidemiology and Global Health, Department of Public Health and Clinical Medicine, Umeå University, 901 85 Umeå, Sweden
g Kintampo Health and Demographic Surveillance System, P.O. Box 230, Kintampo, Ghana
h Iganga-Mayuge Health and Demographic Surveillance System, P.O. Box 111, Iganga, Uganda
i Department of Paediatrics and Child Health, Makerere University College of Health Sciences, P.O. Box 7072, Kampala, Uganda
j Ifakara Health and Demographic Surveillance System, P.O. Box 78373, Ifakara, Tanzania
k Population Health Sciences/Research Support Unit, Faculty of Health Sciences, Aga Khan University (East Africa), Aga Khan Hospital Building, Third Parklands Ave., P.O. Box 30270, Nairobi, Kenya
l NIHR University College London Hospitals Biomedical Research Centre, UCL Institute of Neurology, Queen Square, London WC1N 3BG and Epilepsy Society, Chalfont St. Peter SL9 8ES, Bucks, UK
m Stichting Epilepsie Instellingen Nederland-SEIN, 2103SW Heemstede, Netherlands
n Neurosciences Unit, UCL Institute of Child Health, WC1E 6BT London, UK
o Department of Psychiatry, University of Oxford, OX3 7JX Oxford, UK

Article info

Article history:
Accepted 28 July 2015
Available online 20 August 2015

Keywords:
Electroencephalographic features
Active convulsive epilepsy
Risk factors
Africa

Highlights

- Electroencephalographic abnormalities are common in Africans with epilepsy, with an adjusted prevalence of 2.7 (95% confidence interval, 2.5–2.9) per 1000 population.
- Electroencephalographic abnormalities are associated with preventable factors such as adverse perinatal events and frequent seizures.
- Electroencephalography is helpful in identifying focal epilepsy in Africa, where timing of focal aetiologies is problematic and there is a lack of neuroimaging services.

Abstract

Objective: We investigated the prevalence and pattern of electroencephalographic (EEG) features of epilepsy and the associated factors in Africans with active convulsive epilepsy (ACE).

Methods: We characterized electroencephalographic features and determined associated factors in a sample of people with ACE in five African sites. Mixed-effects modified Poisson regression model was used to determine factors associated with abnormal EEGs.

Results: Recordings were performed on 1426 people of whom 751 (53%) had abnormal EEGs, being an adjusted prevalence of 2.7 (95% confidence interval (95% CI), 2.5–2.9) per 1000. 52% of the abnormal EEGs had focal features (75% with temporal lobe involvement). The frequency and pattern of changes differed with site. Abnormal EEGs were associated with adverse perinatal events (risk ratio (RR) = 1.19 (95% CI, 1.07–1.33)), cognitive impairments (RR = 1.50 (95% CI, 1.30–1.73)), use of anti-epileptic drugs (RR = 1.25 (95% CI, 1.05–1.49)), focal seizures (RR = 1.09 (95% CI, 1.00–1.19)) and seizure frequency (RR = 1.18 (95% CI, 1.10–1.26) for daily seizures; RR = 1.22 (95% CI, 1.10–1.35) for weekly seizures and

http://dx.doi.org/10.1016/j.clinph.2015.07.033
1388-2457/© 2016 The Authors. Published by Elsevier Ltd. on behalf of International Federation of Clinical Neurophysiology.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
1. Introduction

Epilepsy in Africa is associated with significant morbidity and mortality and a large treatment gap (Newton and Garcia, 2012). Focal features defined by seizure semiology and neurological deficits are common in people with epilepsy from Africa and may be related to perinatal complications, head injuries, and central nervous system infections (Kariuki et al., 2014). Active convulsive epilepsy (ACE) in Africa is associated with childhood onset in 60% of cases, convulsive status epilepticus in about 30%, non-adherence to treatment in 60% and psychosocial problems such as being single in over 60% (Mbuba et al., 2012; Kariuki et al., 2015b). The pattern of neurophysiological features and their association with clinical and psychosocial factors have not been fully ascertained in low and middle-income countries.

Electroencephalography (EEG) is a well-established investigation for evaluating epilepsy and is useful in confirming the diagnosis, classifying seizures, and identifying epilepsy syndromes and epileptogenic zones (Fish and Spencer, 1995). The proportion of abnormal EEGs varies between epilepsy syndromes and may differ between hospital- and community-based samples (Binnie and Stefan, 2003). In a broad sample of people with different types of epilepsy, the yield of interictal epileptiform activity in a single 30-min awake EEG recording is up to 50%, although there is substantial variability between individuals (Cockerell et al., 1996; Binnie and Stefan, 2003). The diagnostic yield of EEG can be improved through increased recording time, serial recordings, sleep and activation procedures such as hyperventilation and photic stimulation (Nuwer, 2012).

In Kenya, the EEG was abnormal in 41% of people with ACE (Munyoki et al., 2010), but this study did not relate the EEG findings to medical and psychosocial factors and cannot be extrapolated to other African settings, where clinical features and risk factors of epilepsy may differ (Ngugi et al., 2013; Kariuki et al., 2014). EEG services are becoming more readily available in Africa and are more common than neuroimaging (Wilmshurst et al., 2011). Studies characterizing the patterns of EEG abnormalities and their clinical and psychosocial correlates may contribute to improving the evaluation and management of epilepsy.

We performed EEGs on people with ACE in five African sites to determine prevalence and patterns of abnormality and to characterize the clinical and psychosocial correlates. We further determined whether these factors differed across these sites.

2. Methods

2.1. Population and sites

We performed EEG on people with ACE identified from a previous epidemiological survey conducted across five sites in Africa; (Agincourt in South Africa; Ifakara in Tanzania; Iganga in Uganda; Kilifi in Kenya and Kintampo in Ghana) (Ngugi et al., 2013). Specific details for the participating sites are available at: http://www.indepth-network.org/index.php?option=com_content&task=view&id=753&Itemid=635. The prevalence of ACE ranged from 7 to 15 per 1000 across the five sites and was associated with exposure to multiple parasites (Kamuyu et al., 2014).
Acute encephalopathy was defined as a history of admission to hospital with a febrile malarial, bacterial or viral illness. Adverse perinatal events were defined in those <18 years as a history of delays in crying, breathing and/or breastfeeding at birth.

2.4. Statistical analysis

We performed statistical analysis with STATA version 13.1 (Stata Corp, Texas, USA). Prevalence of EEG abnormalities was determined by dividing abnormalities over the surveyed population expressed per 1000 and accounted for the sensitivity of the three-stage screening methodology. The three-stage methodology involved asking of two seizure questions during a routine door-to-door census in the study area in stage-one, collection of detailed seizure information in those with a history of seizures in stage-two, diagnosis of epilepsy by clinicians in those whose seizure details suggested a possibility of repetitive unprovoked seizures in stage-three (Ngugi et al., 2013). Chi-square and Fisher exact (for infrequent measures) tests compared proportions between groups. Student’s t-test and Mann–Whitney U-test (non-parametric) compared continuous variables such as age. We used modified Poisson regression to compute site-specific relative risks or risk ratios for the associations between EEG features and clinical features and/or psychosocial consequences, with associations reaching a p-value of ≤0.25 entered into a multivariable model adjusted for age and sex. For associations pooled across all five sites, mixed-effects modified Poisson regression model with a random intercept for site was used since the investigated variables and other unmeasured factors may differ across sites. The four categories of seizure frequency (1–4) were considered as non-linear in the fitted models and thus individual risk ratio (RR) for each category were provided compared with the baseline category. We reported RR since they are more easily interpreted in common conditions with a prevalence >10% (Zou, 2004).

2.5. Ethical approval and data security

Ethical approval for this study was granted by the Kenyan Ethical Review Committee and all study participants provided a written-informed consent. Data were anonymised and secured at the research servers of the KEMRI-Wellcome Trust Research Programme.

3. Results

3.1. Description of participants

EEG was performed on 1426 (66%) of 2170 people with ACE whose clinical features were previously described (Fig. 1). Of the 1426 with an EEG, 746 (52%) were males and 679 (48%) were children. Most socio-demographic characteristics, medical history and seizure factors of the 1426 participants with EEG data differed across sites (Tables 1 and 2). There were no differences in features of severe epilepsy between those who provided an EEG sample and those who did not: convulsive status epilepticus (24% vs. 26%, p = 0.577), frequent seizures (20% vs. 19%, p = 0.540) and AED use (37% vs. 35%, p = 0.372).

3.2. Prevalence of EEG abnormalities

EEG abnormalities were present in 751/1426 (53%) in all sites, being highest in Kilifi (293/508 (58%)) and lowest in Iganga (61/147 (42%)) (Table 1−3). EEG abnormalities were similar in males and females (386/746 (52%) vs. 365/680 (54%); p = 0.465). EEG abnormalities were more frequent in children than adults (398/679 (59%) vs. 353/747 (47%); p < 0.0001).

The overall adjusted prevalence of EEG abnormalities per 1000 population was 2.7 (95% CI, 2.5−2.9), being highest in Agincourt and lowest in Iganga (Fig. 2). Focal features formed over half of the prevalence and were most common in Agincourt and lowest in Iganga (Fig. 2). The prevalence of EEG abnormalities differed with age group, increasing steadily with age and then declining after age 28 years. Prevalence of focal EEG features did not change with age (p = 0.269).

3.3. Pattern and distribution of EEG abnormalities

3.3.1. General pattern

Of the 751 subjects with EEG abnormalities, 390 (52%) had focal features, which were commonest in Agincourt (106/111 (96%)) and the occurrence differed with site (Table 3). Most of these focal features had temporal lobe involvement (292/390 (75%)). IEDs were present in 473/751 (63%) of those with abnormal EEG and temporal lobe involvement was common (375/473 (79%)). Multifocal IED were observed in 181/751 (24%) of those with abnormal EEGs.
<table>
<thead>
<tr>
<th>Features</th>
<th>Agincourt Normal EEG (N = 103)</th>
<th>Abnormal EEG (N = 111)</th>
<th>Ifakara Normal EEG (N = 95)</th>
<th>Abnormal EEG (N = 120)</th>
<th>Iganga Normal EEG (N = 86)</th>
<th>Abnormal EEG (N = 61)</th>
<th>Kilifi Normal EEG (N = 215)</th>
<th>Abnormal EEG (N = 293)</th>
<th>Kintampo Normal EEG (N = 176)</th>
<th>Abnormal EEG (N = 166)</th>
<th>All sites Total normal (N = 675)</th>
<th>Total abnormal (N = 751)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Males</td>
<td>55 (53%)</td>
<td>58 (52%)</td>
<td>45 (47%)</td>
<td>50 (42%)</td>
<td>45 (52%)</td>
<td>31 (51%)</td>
<td>119 (55%)</td>
<td>153 (52%)</td>
<td>96 (55%)</td>
<td>94 (57%)</td>
<td>360 (53%)</td>
<td>386 (51%)</td>
</tr>
<tr>
<td>Perinatal complications</td>
<td>0/24 (0%)</td>
<td>5/33 (15%)</td>
<td>2/35 (6%)</td>
<td>7/68 (10%)</td>
<td>5/67 (8%)</td>
<td>0/41 (0%)</td>
<td>4/102 (4%)</td>
<td>14/171 (8%)</td>
<td>12/57 (21%)</td>
<td>30/88 (34%)</td>
<td>23/285 (8%)</td>
<td>56/401 (14%)</td>
</tr>
<tr>
<td>Abnormal pregnancy</td>
<td>1/15 (7%)</td>
<td>0/29 (0%)</td>
<td>5/34 (15%)</td>
<td>6/34 (9%)</td>
<td>9/66 (14%)</td>
<td>1/41 (2%)</td>
<td>18/100 (18%)</td>
<td>40/164 (24%)</td>
<td>11/48 (23%)</td>
<td>10/74 (14%)</td>
<td>44/263 (17%)</td>
<td>57/371 (15%)</td>
</tr>
<tr>
<td>Family history of seizures</td>
<td>8 (8%)</td>
<td>10 (9%)</td>
<td>28 (29%)</td>
<td>38 (32%)</td>
<td>23 (27%)</td>
<td>17 (28%)</td>
<td>56 (26%)</td>
<td>84 (29%)</td>
<td>50 (28%)</td>
<td>53 (32%)</td>
<td>165 (24%)</td>
<td>202 (27%)</td>
</tr>
<tr>
<td>Family history of febrile seizures</td>
<td>1 (1%)</td>
<td>3 (3%)</td>
<td>2 (2%)</td>
<td>2 (2%)</td>
<td>15 (17%)</td>
<td>10 (16%)</td>
<td>26 (12%)</td>
<td>42 (14%)</td>
<td>12 (7%)</td>
<td>13 (8%)</td>
<td>56 (8%)</td>
<td>70 (9%)</td>
</tr>
<tr>
<td>Acute encephalopathy</td>
<td>2 (2%)</td>
<td>2 (2%)</td>
<td>0 (0%)</td>
<td>1 (1%)</td>
<td>17 (20%)</td>
<td>6 (10%)</td>
<td>28 (13%)</td>
<td>81 (28%)</td>
<td>2 (1%)</td>
<td>3 (2%)</td>
<td>49 (7%)</td>
<td>93 (12%)</td>
</tr>
<tr>
<td>Comorbidities of active convulsive epilepsy</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Malnutrition</td>
<td>11 (11%)</td>
<td>12 (11%)</td>
<td>9 (9%)</td>
<td>14 (12%)</td>
<td>17 (20%)</td>
<td>12 (20%)</td>
<td>34 (16%)</td>
<td>51 (17%)</td>
<td>15 (9%)</td>
<td>18 (11%)</td>
<td>86 (13%)</td>
<td>107 (14%)</td>
</tr>
<tr>
<td>Neurological deficits</td>
<td>14 (14%)</td>
<td>27 (24%)</td>
<td>2 (2%)</td>
<td>20 (17%)</td>
<td>4 (5%)</td>
<td>17 (28%)</td>
<td>21 (10%)</td>
<td>64 (22%)</td>
<td>7 (4%)</td>
<td>32 (19%)</td>
<td>48 (7%)</td>
<td>160 (21%)</td>
</tr>
<tr>
<td>Cognitive impairment</td>
<td>18 (17%)</td>
<td>39 (35%)</td>
<td>4 (4%)</td>
<td>23 (19%)</td>
<td>5 (6%)</td>
<td>16 (26%)</td>
<td>26 (12%)</td>
<td>102 (35%)</td>
<td>28 (16%)</td>
<td>62 (37%)</td>
<td>81 (12%)</td>
<td>242 (32%)</td>
</tr>
<tr>
<td>Head injuries</td>
<td>6 (6%)</td>
<td>11/110 (10%)</td>
<td>6/92 (7%)</td>
<td>3/119 (3%)</td>
<td>5/85 (6%)</td>
<td>3/60 (5%)</td>
<td>31/210 (15%)</td>
<td>35/288 (12%)</td>
<td>38 (22%)</td>
<td>49/163 (30%)</td>
<td>86/666 (13%)</td>
<td>101/740 (14%)</td>
</tr>
<tr>
<td>Psychosocial factors and outcomes in active convulsive epilepsy</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Burns</td>
<td>15 (15%)</td>
<td>15 (14%)</td>
<td>16 (17%)</td>
<td>17 (14%)</td>
<td>5 (6%)</td>
<td>5 (8%)</td>
<td>31 (14%)</td>
<td>61 (21%)</td>
<td>24 (14%)</td>
<td>29 (17%)</td>
<td>91 (14%)</td>
<td>127 (17%)</td>
</tr>
<tr>
<td>Un schooled</td>
<td>23 (22%)</td>
<td>32 (29%)</td>
<td>22 (23%)</td>
<td>65 (54%)</td>
<td>33 (38%)</td>
<td>29 (48%)</td>
<td>89 (41%)</td>
<td>145 (49%)</td>
<td>69 (39%)</td>
<td>67 (40%)</td>
<td>236 (35%)</td>
<td>338 (45%)</td>
</tr>
<tr>
<td>Unemployed adults</td>
<td>71/79 (90%)</td>
<td>75/80 (94%)</td>
<td>10/61 (16%)</td>
<td>24/52 (46%)</td>
<td>17/20 (85%)</td>
<td>15/20 (73%)</td>
<td>69/114 (61%)</td>
<td>74/122 (61%)</td>
<td>42/120 (35%)</td>
<td>46/79 (38%)</td>
<td>209/394 (53%)</td>
<td>234/353 (66%)</td>
</tr>
<tr>
<td>Unmarried adults</td>
<td>50/79 (63%)</td>
<td>64/80 (80%)</td>
<td>36/61 (59%)</td>
<td>37/52 (71%)</td>
<td>13/20 (65%)</td>
<td>17/20 (85%)</td>
<td>67/114 (59%)</td>
<td>90/122 (74%)</td>
<td>81/120 (68%)</td>
<td>63/79 (80%)</td>
<td>247/394 (63%)</td>
<td>271/353 (77%)</td>
</tr>
</tbody>
</table>

IQR = interquartile range; EEG = electroencephalography.
Table 2
Seizure types, status epilepticus and treatment of convulsive active epilepsy in those with electroencephalograms.

<table>
<thead>
<tr>
<th>Features</th>
<th>Agincourt</th>
<th>Iganga</th>
<th>Ifakara</th>
<th>Kilifi</th>
<th>Kintampo</th>
<th>Total</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Normal EEG (N = 103)</td>
<td>Abnormal EEG (N = 111)</td>
<td>Normal EEG (N = 95)</td>
<td>Abnormal EEG (N = 120)</td>
<td>Normal EEG (N = 86)</td>
<td>Abnormal EEG (N = 61)</td>
<td>Normal EEG (N = 176)</td>
</tr>
<tr>
<td>All generalized seizures</td>
<td>55 (53%)</td>
<td>66 (59%)</td>
<td>54 (57%)</td>
<td>59 (49%)</td>
<td>57 (66%)</td>
<td>45 (74%)</td>
<td>60 (28%)</td>
</tr>
<tr>
<td>Generalized tonic-clonic seizures</td>
<td>45 (44%)</td>
<td>60 (54%)</td>
<td>47 (50%)</td>
<td>51 (43%)</td>
<td>51 (59%)</td>
<td>43 (70%)</td>
<td>52 (24%)</td>
</tr>
<tr>
<td>Generalized other convulsive seizures</td>
<td>5 (5%)</td>
<td>4 (4%)</td>
<td>0 (0%)</td>
<td>1 (1%)</td>
<td>2 (2%)</td>
<td>1 (2%)</td>
<td>8 (4%)</td>
</tr>
<tr>
<td>Generalized absence seizures</td>
<td>8 (8%)</td>
<td>12 (11%)</td>
<td>2 (2%)</td>
<td>3 (3%)</td>
<td>2 (2%)</td>
<td>2 (3%)</td>
<td>2 (1%)</td>
</tr>
<tr>
<td>Generalized unspecified seizures</td>
<td>2 (2%)</td>
<td>1 (1%)</td>
<td>3 (3%)</td>
<td>1 (2%)</td>
<td>0 (0%)</td>
<td>3 (1%)</td>
<td>2 (1%)</td>
</tr>
<tr>
<td>Focal seizures</td>
<td>46 (45%)</td>
<td>46 (41%)</td>
<td>23 (24%)</td>
<td>42 (35%)</td>
<td>26 (30%)</td>
<td>19 (31%)</td>
<td>142 (66%)</td>
</tr>
<tr>
<td>Focal with generalization</td>
<td>46 (45%)</td>
<td>42 (38%)</td>
<td>16 (17%)</td>
<td>33 (28%)</td>
<td>21 (24%)</td>
<td>13 (21%)</td>
<td>64 (30%)</td>
</tr>
<tr>
<td>Focal convulsive seizures</td>
<td>1 (1%)</td>
<td>2 (2%)</td>
<td>2 (2%)</td>
<td>4 (3%)</td>
<td>1 (1%)</td>
<td>1 (2%)</td>
<td>48 (22%)</td>
</tr>
<tr>
<td>Focal dyscognitive seizures</td>
<td>1 (1%)</td>
<td>7 (6%)</td>
<td>1 (1%)</td>
<td>6 (5%)</td>
<td>3 (3%)</td>
<td>6 (10%)</td>
<td>26 (12%)</td>
</tr>
<tr>
<td>Focal sensory seizures</td>
<td>0 (0%)</td>
<td>0 (0%)</td>
<td>1 (1%)</td>
<td>1 (1%)</td>
<td>0 (0%)</td>
<td>0 (0%)</td>
<td>5 (2%)</td>
</tr>
<tr>
<td>Focal unspecified seizures</td>
<td>0 (0%)</td>
<td>0 (0%)</td>
<td>3 (3%)</td>
<td>4 (3%)</td>
<td>2 (2%)</td>
<td>0 (0%)</td>
<td>9 (4%)</td>
</tr>
<tr>
<td>Other unspecified seizures</td>
<td>1 (1%)</td>
<td>1 (1%)</td>
<td>0 (0%)</td>
<td>1 (1%)</td>
<td>0 (0%)</td>
<td>0 (0%)</td>
<td>3 (1%)</td>
</tr>
<tr>
<td>Other convulsive seizures</td>
<td>0 (0%)</td>
<td>0 (0%)</td>
<td>0 (0%)</td>
<td>0 (0%)</td>
<td>1 (1%)</td>
<td>0 (0%)</td>
<td>5 (2%)</td>
</tr>
<tr>
<td>Impaired consciousness</td>
<td>0 (0%)</td>
<td>0 (0%)</td>
<td>0 (0%)</td>
<td>0 (0%)</td>
<td>0 (0%)</td>
<td>0 (0%)</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>Status epilepticus and use of AEDs</td>
<td>29/85 (34%)</td>
<td>24/89 (27%)</td>
<td>2/70 (3%)</td>
<td>4/87 (5%)</td>
<td>37/79 (47%)</td>
<td>18/59 (31%)</td>
<td>60/200 (30%)</td>
</tr>
<tr>
<td>Status epilepticus</td>
<td>2/85 (2%)</td>
<td>6/89 (7%)</td>
<td>0/71 (0%)</td>
<td>1/88 (1%)</td>
<td>17/79 (22%)</td>
<td>7/59 (12%)</td>
<td>39/201 (19%)</td>
</tr>
<tr>
<td>Focal seizures</td>
<td>0/85 (0%)</td>
<td>0/89 (0%)</td>
<td>0/71 (0%)</td>
<td>0/88 (0%)</td>
<td>0/79 (0%)</td>
<td>0/59 (0%)</td>
<td>0/201 (0%)</td>
</tr>
<tr>
<td>AEDs use</td>
<td>57 (55%)</td>
<td>69 (62%)</td>
<td>38 (40%)</td>
<td>68 (57%)</td>
<td>15 (17%)</td>
<td>18 (30%)</td>
<td>70 (33%)</td>
</tr>
</tbody>
</table>

AEDs = anti-epileptic drugs; EEG = electroencephalography.
while other non-specific EEG features were observed in 435/751 (58%) of those with abnormal EEGs.

3.3.2. Distribution across epilepsy and medical factors

EEG abnormalities were more frequent in those with a history of adverse perinatal events (aged ≤ 18 years) (56/79 (71%) vs. 345/607 (57%); \( p = 0.017 \); Table 1) and acute encephalopathy (93/142 (65%) vs. 658/1284 (51%); \( p = 0.001 \)) compared to those without such histories. Abnormalities were commoner in focal seizures than those without these seizures (374/669 (56%) vs. 377/757 (50%); \( p = 0.021 \)) and in those with neurological deficits than in those without (160/208 (77%) vs. 591/1218 (49%); \( p < 0.0001 \)). Abnormalities were similar in those with convulsive status epilepticus compared to those without (\( p = 0.487 \)) (Table 2), but were more common in those with a history of febrile convulsive status epilepticus compared to those without convulsive epilepticus status (105/165 (64%) vs. 561/1096 (51%); \( p = 0.003 \)) and were associated with seizure frequency (univariate RR = 1.64 (95% CI, 1.46–1.83) for daily seizures; \( RR = 1.77 \) (95% CI, 1.47–2.14) for weekly seizures and \( RR = 1.44 \) (95% CI, 1.24–1.67) for monthly seizures). Abnormalities were observed more often in those with self-reported use of AED compared to those without (322/526 (61%) vs. 429/900 (48%); \( p < 0.0001 \)) (Table 2).

3.3.3. Focal EEG features and epilepsy and medical factors

Focal features were associated with an earlier onset of seizures (univariate RR = 0.99 (95% CI, 0.98–0.99); \( p < 0.0001 \)) and increased seizure frequency (univariate RR = 1.731 (95% CI, 1.43–2.10) for daily seizures; \( RR = 2.01 \) (95% CI, 1.54–2.62 for weekly seizures and \( RR = 1.61 \) (95% CI, 1.25–2.09) for monthly seizures), among those with abnormal EEG. Focal changes were similar in those with and without a history of adverse perinatal events (28/55 (51%) vs. 178/344 (52%); \( p = 0.250 \)) and acute encephalopathy (40/93 (43%) vs. 350/658 (53%); \( p = 0.076 \)). Focal features occurred in 196/375 (52%) of those with generalized seizure semiology and abnormal EEG.

Table 3

<table>
<thead>
<tr>
<th>Features</th>
<th>Agincourt (( N = 111 ))</th>
<th>Ifakara (( N = 120 ))</th>
<th>Iganga (( N = 61 ))</th>
<th>Kilifi (( N = 293 ))</th>
<th>Kintampo (( N = 166 ))</th>
<th>All sites (( N = 751 ))</th>
<th>( p )-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Focal EEG features</td>
<td>106 (95%)</td>
<td>72 (60%)</td>
<td>23 (38%)</td>
<td>115 (39%)</td>
<td>74 (45%)</td>
<td>390 (52%)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Interictal epileptiform discharges</td>
<td>58 (52%)</td>
<td>79 (66%)</td>
<td>36 (59%)</td>
<td>170 (58%)</td>
<td>130 (78%)</td>
<td>473 (63%)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Multifocal epileptiform discharges</td>
<td>26 (23%)</td>
<td>36 (30%)</td>
<td>19 (31%)</td>
<td>65 (22%)</td>
<td>35 (21%)</td>
<td>181 (24%)</td>
<td>0.250</td>
</tr>
<tr>
<td>Generalized epileptiform discharges</td>
<td>5 (5%)</td>
<td>16 (13%)</td>
<td>9 (15%)</td>
<td>39 (13%)</td>
<td>46 (28%)</td>
<td>115 (15%)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Other EEG features</td>
<td>87 (78%)</td>
<td>83 (69%)</td>
<td>28 (46%)</td>
<td>190 (65%)</td>
<td>47 (28%)</td>
<td>435 (58%)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Hyperventilation</td>
<td>20/106 (19%)</td>
<td>25/58 (26%)</td>
<td>5/30 (17%)</td>
<td>30/235 (13%)</td>
<td>41/148 (28%)</td>
<td>12/617 (20%)</td>
<td>0.004</td>
</tr>
<tr>
<td>Photosensitivity</td>
<td>6/108 (6%)</td>
<td>15/115 (13%)</td>
<td>1/10 (10%)</td>
<td>20/280 (7%)</td>
<td>0/4 (0%)</td>
<td>42/517 (8%)</td>
<td>0.245</td>
</tr>
</tbody>
</table>

EEG = electroencephalography; The total population (\( N \)) is the abnormal EEG features in each site. The features are not mutually exclusive.

Fig. 2. Prevalence of electroencephalographic features in active convulsive epilepsy in Africa by focal features and site. The prevalence was heterogeneous across the five sites being highest in Kintampo; and increased with age up to 28 years then declined.
3.4. Activation procedures in EEG

Hyperventilation provoked abnormalities in 121/617 (20%) of abnormal EEGs, this being most common in Kintampo (41/148 (28%), with significant differences across the five sites (Table 3). Abnormal hyperventilation responses were associated with the age (univariate RR = 0.97 (95% CI, 0.96–0.98); p < 0.0001) and were significantly greater in those with generalized IEDs than those without (47/79 (59%) vs. 80/538 (15%); p < 0.0001). Photosensitivity was seen in 42/517 (8%) with abnormal EEGs being most common in Ifakara (15/115 (13%), and was similar across the sites. Photosensitivity was significantly more common in children than adults (30/264 (11%) vs. 12/253 (5%); p = 0.006) and in those with multifocal IEDs compared to those with (31/126 (26%) vs. 11/397 (3%); p < 0.0001)

4. Factors associated with EEG abnormalities

Several factors were associated with abnormal EEG features in the univariate analysis (Table 4). After including variables with a p-value of ≤0.25 in a multivariable model, the following were independently associated with abnormal EEGs for all participants from the five sites combined: adverse perinatal events (RR = 1.19 (95% CI, 1.07–1.33)), cognitive impairments (1.50 (95% CI, 1.30–1.73)), use of AEDs (RR = 1.25 (95% CI, 1.05–1.49)), focal seizures (RR = 1.10 (95% CI = 1.00–1.19)) and seizure frequency (RR = 1.18 (95% CI, 1.10–1.26) for daily seizures; RR = 1.22 (0.73–1.60) for monthly seizures). Factors independently associated with abnormal EEGs within the sites are shown in Table 5. None was significant in every one of the five sites.

4. Discussion

This study suggests that the prevalence of EEG abnormalities in Africans with ACE is high; particularly in children and that they differ significantly between sites. EEG abnormalities were associated with perinatal complications, neurocognitive impairments and epilepsy related factors such as AED use and seizure frequency. In the within site analysis, none of these factors was associated with abnormal EEG across all the five sites, with only AED use appearing significant in three sites.

4.1. Prevalence of EEG abnormalities

The prevalence of EEG abnormalities is higher than in previous studies (King et al., 1998). In our sample about 50% of people with abnormal EEG for whom generalized seizure semiology was described in the study had EEG performed. It was observed that a few patients had EEG performed while drowsy or in light sleep which may have improved the yield (but this was not systematically documented during the study).

The heterogeneity in prevalence across the sites may be related to differences in the aetiology, e.g. falciparum malaria in Kilifi and Ifakara and head injuries in Agincourt, and epilepsy factors reported previously (Kariuki et al., 2014). All recordings from the five sites were rated by one individual with expertise in EEG and epilepsy, following a standardized protocol. Over half of people with abnormal EEG in ACE in this study may benefit from improved diagnosis and management, although EEG are not routinely performed in Africans hospitalized with epilepsy (Kariuki et al., 2015a).

4.2. Clinical utility of EEG

The EEG may help in classifying epilepsy as focal or generalized (King et al., 1998). In our sample about 50% of people with abnormal EEG for whom generalized seizure semiology was described in different locations.
by site specific interventions. EEGs may help identify those at risk for perinatal complications and infections, which could be preventable. It is important to note that EEG abnormalities in ACE may be related to head trauma, which may result in falls or accidents. These findings taken together suggest that EEG abnormalities in ACE are associated with the frequency of EEG abnormalities in children, some of whom may die before reaching adulthood. Focal sei

4.3. Factors associated with EEG abnormalities across all sites

The frequency of abnormal EEGs in ACE was associated with several epilepsy-related and clinical factors in a pooled analysis of the five sites. Adverse perinatal events are a recognized cause of epilepsy in Africa and can lead to persistent brain damage (Ngugi et al., 2013), which may be associated with EEG changes (Pressler et al., 2005). This may account for the significantly higher frequency of EEG abnormalities in children, some of whom may die before reaching adulthood. Focal seizures could be a marker of localized brain damage by central nervous infections and injuries, which may be reflected in both acute and chronic EEG abnormalities (Crawley et al., 2001). AED use may be a surrogate marker of severe epilepsy, hence its association with EEG abnormalities, which are also related to seizure frequency (Kariuki et al., 2014). The association between an abnormal EEG and cognitive impairment confirms the negative impact which epilepsy may have on intellectual function and behavior (Aldenkamp, 2006).

4.4. Factors associated with EEG abnormalities within the sites

In the within site analysis, none of these factors was associated with abnormal EEG across all the five sites. This highlights the importance of site-specific preventative and management interventions for those with abnormal EEGs in ACE. For example, febrile status epilepticus was important in Ifakara, a malaria endemic area, where malaria may be the main cause for status epilepticus (Sadarangani et al., 2008). Head injuries were an important association in Agincourt, where most people with ACE were adults (Kariuki et al., 2014), and indulge in violent or risk behavior that can result in falls or accidents. These findings taken together suggest that EEG abnormalities in ACE may be related to head trauma, perinatal complications and infections, which could be preventable by site specific interventions. EEGs may help identify those at risk of cognitive impairments, which may be a consequence of ACE or use of AEDs.

4.5. Strengths and limitations

The large sample size, providing sufficient power to measure associations between clinical groups is the major strength of the study. Epilepsy cases were identified using a standard methodology and one experienced clinical researcher (experienced in reading EEGs) rated all EEGs following a standardized protocol. The pooled analysis of factors associated with EEG abnormalities is reliable since we accounted for clustering within the sites. A limitation is that we only performed a single routine EEG in each individual. For logistic reasons we did not do serial or sleep EEGs recording, which may have provided a higher diagnostic yield. The cognitive impairment in this study should be interpreted carefully since we assessed it by clinical evaluation of mental status rather than by standardized neuropsychological tests.

4.6. Conclusion

EEG abnormalities are common in Africans with ACE, but the prevalence and proportion of focal features vary according to site, probably related to specific aetiological and clinical features of epilepsy in these areas. The EEG features have clinical utility, particularly in helping to identify focal epilepsies that can be further evaluated with neuroimaging. EEG abnormalities are associated with perinatal complications and severe epilepsy, and may predict neurocognitive outcomes among those with ACE. Future studies should apply EEG findings along with other clinical and neuroimaging features to improve the understanding and management of epilepsy in Africa.

Acknowledgments

This study was supported by the Wellcome Trust, through a Senior Research Fellowship (083744) to C.R.N. S.K. is supported by the Wellcome Trust (099782/Z/12/Z). J.W.S. is supported by the Dr. Marvin Weil Epilepsy Research Fund and is based at UCLH/UCL, which received a proportion of funding from the Department of Health’s NIHR Biomedical Research Centres funding scheme. The sponsors had no role in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. We are grateful to Doctor Gail Bell for appraising the manuscript. This paper is published with permission of the director of KEMRI.

Conflict of interest: None of the authors have potential conflicts of interest to be disclosed.

Appendix A. The SEEDS investigators

Agincourt HDSS, South Africa: Ryan Wagner, MSc (Agincourt, South Africa, PI for Agincourt Site), Rhian Twine, MPH (Agincourt, South Africa, Data Collection), Myles Connor, PhD (Agincourt, South Africa, Data Collection), Myles Connor, PhD (Agincourt, South Africa, Data Collection).
South Africa, data collection); F. Xavier Gómez Olivé, MSc (Agincourt, South Africa, data collection), Mark Collinson, PhD (Agincourt, South Africa, Data Collection), Stephen Tollman, PhD (Agincourt, South Africa, Data Collection);

Ifakara HDSS, Tanzania: Honratio Masanja, PhD (Ifakara, Tanzania, PI for Ifakara Site); Alexander Mathew (deceased), MSc, (Ifakara, Tanzania, PI for Ifakara Site);

Iganga-Mayuge HDSS, Uganda: Angelina Kakooza, MD (Kampala, Uganda, PI for Agincourt site), George Pariyo (Kampala, Uganda, Data Collection), Stefan Peterson (Kampala, Uganda, Data Collection), Donald Ndoumughenyi (Kampala, Uganda, Data Collection);

Kilifi HDSS, Kenya: Symon M. Kariuki, MSc (Kilifi, Kenya, PI for Kilifi Site); Anthony K. Ngugi, PhD (Nairobi, Kenya, Co-PI for Kilifi Site); Rachael Odhiambo, MSc (Kilifi, Kenya, Data Manager); Eddie Cheng, MSc (Kilifi, Kenya, Data Collection); Martin Chabi, MMED (Nairobi, Kenya, Data Collection); Evasius Bauni, PhD (Kilifi, Kenya, Data Collection), Gathoni Kamuyu, MSc (Kilifi, Kenya, Performing Parasitic Assays); Victor Mung’ala Odera (deceased), PhD (Kilifi, Kenya, Advisor on Study Design); James O. Mageto, BSc (Kilifi, Kenya, Helped with Parasitic Assays); Charles R. Newton, MD (Oxford, UK, Senior Supervisor and Principal Investigator);

Kintampo HDSS, Ghana: Ken Ae-Ngibise, MSc (Kintampo, Ghana, data collection); Bright Akpala, MPhil (Kintampo, Ghana, data collection); Albert Akpala, MMED (Kintampo, Ghana, data collection); Francis Aghokey, BSc (Kintampo, Ghana, data collection); Patrick Adjei, MSc (Kintampo, Ghana, data collection); Seth Owusu-Agyei, PhD (Kintampo, Ghana, data collection);

London School of Hygiene and Tropical Medicine, UK: Christian Bottomley, PhD (LSHTM, London, UK, Advise on statistical analysis); Immo Kleinschmidt, PhD (LSHTM, London, UK, Advise on Study Design);

King’s College London, UK: Victor C.K. Doku, PhD (London, UK, Study Design);

Swiss Tropical Institute, Switzerland: Peter Odermatt, PhD (Swiss TPH, Advisor on Public Health);

University College London, UK: Brian Neville, FRCP (London, UK, Study design); Josef W. Sander, FRCP (London, UK, Study design); Steve White, PhD (London, UK, Interpretation of EEG);

National Institutes of Health, USA: Thomas Nutman, MD (NIH, USA, Advisor on Parasitic Assays);

Centers for Disease Control and Prevention, USA: Patricia Wilkins, PhD (CDC, USA, Advisor on Parasitic Assays); John Noh, MD (CDC, USA, Advisor on Parasitic Assays).

References


ILAE. Guidelines for epidemiologic studies on epilepsy. Commission on Epidemiology and Prognosis, International League Against Epilepsy. Epilepsia 1993;34:392–6.


